We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
Read MoreHide Full Article
Pfizer (PFE - Free Report) and its partner Merck KGaA (MKGAF - Free Report) announced that the supplemental Biologics License Application (sBLA) for Bavencio (avelumab), in combination with Pfizer’s another cancer drug Inlyta (axitinib) was granted priority review by the FDA. The sBLA is seeking approval of the drug combination as a treatment for advanced renal cell carcinoma (“RCC”), the most common form of kidney cancer. The FDA’s decision is expected in June 2019.
While Bavencio is approved for treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma in patients whose disease progressed following a chemotherapy, Inlyta is approved for second-line treatment of advanced RCC.
The sBLA was filed based on interim data from the phase III JAVELIN Renal 101 study which evaluated the Bavencio/Inlyta combination against Pfizer’s older kidney cancer drug Sutent. Data from the study, presented in the past, showed that the combination regimen led to statistically significant improvement in progression-free survival (“PFS”) in patients whose tumors had PD-L1 expression greater than 1% as well as in the entire study population regardless of PD-L1 tumor expression. The ongoing study is currently evaluating the regimen for improvement in overall survival (“OS”).
We note that Pfizer is developing Bavencio in JAVELIN program, which consists of at least 30 clinical studies evaluating the drug in more than 15 different cancer indications. Although Bavencio is approved two small cancer indication, successful development in the ongoing studies will help its label to expand into major indications. The company considers Bavencio, an anti PD-L1 antibody, as a key driver of its long-term growth. It is mainly focusing on developing the drug in combination with its other targeted therapies. PD-1/PD-L1 targeted therapies hold tremendous potential as evident from the growth of Merck’s (MRK - Free Report) Keytruda and Bristol-Myers’ (BMY - Free Report) Opdivo, which are PD-1 inhibitors.
Pfizer’s stock has risen 2.1% in the past six months, in line with the industry’s increase in the same time frame.
In a separate press release, Pfizer announced that it will present data from the phase III ARCHES study evaluating Xtandi for treating metastatic hormone-sensitive prostate cancer (mHSPC). The company stated that the drug in combination with androgen deprivation therapy (“ADT”) significantly reduced the risk of radiographic progression or death by 61% compared to ADT alone.
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Image: Bigstock
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
Pfizer (PFE - Free Report) and its partner Merck KGaA (MKGAF - Free Report) announced that the supplemental Biologics License Application (sBLA) for Bavencio (avelumab), in combination with Pfizer’s another cancer drug Inlyta (axitinib) was granted priority review by the FDA. The sBLA is seeking approval of the drug combination as a treatment for advanced renal cell carcinoma (“RCC”), the most common form of kidney cancer. The FDA’s decision is expected in June 2019.
While Bavencio is approved for treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma in patients whose disease progressed following a chemotherapy, Inlyta is approved for second-line treatment of advanced RCC.
The sBLA was filed based on interim data from the phase III JAVELIN Renal 101 study which evaluated the Bavencio/Inlyta combination against Pfizer’s older kidney cancer drug Sutent. Data from the study, presented in the past, showed that the combination regimen led to statistically significant improvement in progression-free survival (“PFS”) in patients whose tumors had PD-L1 expression greater than 1% as well as in the entire study population regardless of PD-L1 tumor expression. The ongoing study is currently evaluating the regimen for improvement in overall survival (“OS”).
We note that Pfizer is developing Bavencio in JAVELIN program, which consists of at least 30 clinical studies evaluating the drug in more than 15 different cancer indications. Although Bavencio is approved two small cancer indication, successful development in the ongoing studies will help its label to expand into major indications. The company considers Bavencio, an anti PD-L1 antibody, as a key driver of its long-term growth. It is mainly focusing on developing the drug in combination with its other targeted therapies. PD-1/PD-L1 targeted therapies hold tremendous potential as evident from the growth of Merck’s (MRK - Free Report) Keytruda and Bristol-Myers’ (BMY - Free Report) Opdivo, which are PD-1 inhibitors.
Pfizer’s stock has risen 2.1% in the past six months, in line with the industry’s increase in the same time frame.
In a separate press release, Pfizer announced that it will present data from the phase III ARCHES study evaluating Xtandi for treating metastatic hormone-sensitive prostate cancer (mHSPC). The company stated that the drug in combination with androgen deprivation therapy (“ADT”) significantly reduced the risk of radiographic progression or death by 61% compared to ADT alone.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free – See the Stocks It Turned Up for Today >>